Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019
- Saturday, September 28, 2019, 7:12
- PR Newswire
- Add a comment
SALT LAKE CITY, Sept. 28, 2019 /PRNewswire/ — Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented new data from the ongoing Phase 1 study evaluating the maximum tolerated dose (MTD) of…
About the Author
admin has written 20652 stories on this site.